Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- Your prostate cancer has spread to other parts of the body and is getting worse despite hormone therapy.
- You have already tried at least one newer hormone therapy drug (like abiraterone, enzalutamide, darolutamide, or apalutamide).
- You have not taken any drug that targets a protein complex called PRC2 (such as EZH2 inhibitors).
- You have not had a type of treatment called radioligand therapy for your prostate cancer (unless you are in a specific part of the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This trial tests a new drug, tulmimetostat, combined with standard hormone therapies like darolutamide or abiraterone for men with metastatic prostate cancer that still responds to hormone treatment. The goal is to see if the combination works better than standard therapy alone.
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Hear when a new Progressive Metastatic Castrate Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.